QIAGEN (QGEN) Announces CE Mark on Next Generation Molecular Diagnostic for KRAS Analysis
More News related to QGEN
- QIAGEN and British Veterinary Laboratories Agency Expand Partnership in Veterinary Testing
- Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Third Quarter 2009 Financial Results Call Set for November 10
- Cowen & Co Initiates Coverage on Qiagen (QGEN) with an Outperform
- BioInformatics, LLC New Report - The Market Outlook for Research Products in FY2010
- Don't Miss Out! Two Weeks Left to Register for the 2010 IR Global Rankings
QIAGEN (NASDAQ: QGEN) announced the official launch of its next-generation CE-labelled assay for KRAS testing in colorectal cancer patients. In addition, the company gave an update on the pipeline of its regulated assay portfolio for personalized cancer treatment based upon the Pyrosequencing technology. As evidenced by the significant expansion of its portfolio in this area, the company intends to provide its customers a broad portfolio of fully CE-marked sample-to-result technologies for tumor mutation profiling for various cancers. QIAGEN believes that these solutions will provide significant value to oncology diagnostics and to research.
QIAGEN N.V. (QIAGEN) is a provider of technologies and products for preanalytical sample preparation and linked molecular assay solutions.[SM]
Related Categories
Corporate NewsStocks Mentioned
+0.13Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
